Valuation: Caplin Point Laboratories Limited

Market Cap 189B 1.98B 1.71B 1.61B 1.46B 2.74B 2.79B 18.82B 7.35B 94.52B 7.42B 7.26B 315B P/E 2026
17.9x
P/E 2027 * 25.6x
Enterprise Value 189B 1.98B 1.71B 1.61B 1.46B 2.74B 2.79B 18.82B 7.35B 94.52B 7.42B 7.26B 315B EV / Sales 2026
5.23x
EV / Sales 2027 * 7.54x
Free-Float
26.39%
Yield 2026 *
-
Yield 2027 * 0.16%
1 day-0.71%
1 week-3.67%
Current month-1.36%
1 month-6.43%
3 months+24.10%
6 months+43.16%
Current year+34.73%
1 week 2,381
Extreme 2381
2,662.8
1 month 2,381
Extreme 2381
2,680
Current year 1,502.45
Extreme 1502.45
2,700
1 year 1,502.45
Extreme 1502.45
2,700
3 years 950
Extreme 950
2,700
5 years 575
Extreme 575
2,700
10 years 180
Extreme 180
2,700
Manager TitleAgeSince
Chief Executive Officer 71 2015-03-27
Director of Finance/CFO - 2016-02-18
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 73 2010-01-26
Director/Board Member - 2025-11-04
Director/Board Member 71 2015-03-27
Change 5-day change 1-year change 3-year change Capi.($)
-0.71%-3.67%+16.26%+144.84% 1.97B
-0.10%-0.77%+17.58%+70.16% 48.43B
-3.26%-5.31%+52.47%+114.13% 39.72B
-0.60%-0.94%-7.29%+17.35% 12.25B
-2.75%+1.88%+14.81%+76.92% 11.84B
-0.58%-0.77%+29.90%+135.00% 9.06B
+1.56%+5.52%+23.69%+41.38% 7.57B
+0.52%+2.08%+42.23%-13.42% 7.18B
-0.07%+1.72%+13.39%+190.65% 6.84B
-2.51%-3.14%-30.53%+23.54% 5.77B
Average -0.85%+0.98%+17.25%+80.06% 15.06B
Weighted average by Cap. -1.20%+0.95%+24.71%+81.13%

Financials

2026 2027 *
Net sales 21.28B 223M 193M 181M 165M 309M 315M 2.12B 830M 10.67B 837M 819M 35.54B 25.01B 262M 227M 213M 194M 364M 370M 2.5B 975M 12.54B 984M 963M 41.77B
Net income 6.16B 64.58M 55.83M 52.48M 47.72M 89.62M 91.17M 615M 240M 3.09B 242M 237M 10.29B 7.37B 77.23M 66.77M 62.76M 57.07M 107M 109M 735M 287M 3.69B 290M 284M 12.31B
Net Debt - -
Logo Caplin Point Laboratories Limited
Caplin Point Laboratories Limited is an India-based pharmaceutical company with a business model catering predominantly to emerging markets of Latin America and Africa. The Company has also entered regulated markets such as the United States through its Subsidiary, Caplin Steriles Limited. The Company's operations include research & development and manufacturing of finished formulations, active pharmaceutical ingredients (APIs), clinical research, front-end generic presence in Latin America, brand marketing in Francophone Africa and a USFDA/EU-GMP approved injectable facility. In the Regulated Markets, its products include liquid & lyophilized vials, pre-filled syringes, three-pc ophthalmic droppers and pre-mix bags. In the Emerging Markets, its products include tablets, dry syrups - bottles, soft gels, capsules, suppositories, liquid syrups - bottles, liquid injectables in ampoules & vials, lyophilized vials, prefilled syringes (PFS), and emulsion injection in ampoules & vials.
Employees
3,966
Date Price Change Volume
26-08-14 ₹2,480.60 -0.71% 2,916
26-08-13 ₹2,498.25 +0.93% 15,912
26-08-12 ₹2,475.20 -5.68% 19,726
26-08-11 ₹2,624.15 +0.08% 4,811
26-08-10 ₹2,622.00 +1.82% 8,448
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2,480.60INR
Average target price
2,505.00INR
Spread / Average Target
+0.98%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CAPLIPOINT Stock